Detection of melanoma

This multicentre, prospective, blinded clinical study was conducted in the US and Europe to investigate the effectiveness and safety of the Nevisense system to distinguish benign lesions from melanoma

Researchers investigated the effectiveness of melanoma detection (Photograph: Lea Paterson/Science Photo Library)
Researchers investigated the effectiveness of melanoma detection (Photograph: Lea Paterson/Science Photo Library)
The Nevisense system uses electrical impedance spectroscopy for non-visual detection of malignant melanoma.

There were 1,951 participants in the study with a total of 2,416 lesions. Of these, 1,943 lesions were eligible to be included.

The study used Nevisense to examine all eligible skin lesions, which were also photographed, removed by biopsy and examined histopathologically. Clinical follow-up was conducted between four and 10 days after initial measurement.

The Nevisense system correctly predicted 256 of 265 confirmed melanomas, with a sensitivity of 96.6%. The positive and negative predictive value of Nevisense was found to be 21.1% and 98.2%, respectively.

It also correctly predicted all 55 confirmed non-melanoma skin cancer lesions (48 basal cell carcinoma and seven squamous cell carcinoma), with a sensitivity of 100%.

The researchers concluded that the Nevisense system is accurate and safe for clinicians to use as an aid in detecting cutaneous melanoma.

Malvehy J, Hauschild A, Curiel-Lewandrowski C et al. Br J Dermatol. Published online May 19, 2014. doi: 10.1111/bjd.13121

Read these next

Expert Opinion: Latest developments in skin cancer screening

Expert Opinion: Latest developments in skin cancer screening

Dr Stephen Hayes discusses the outcomes of a recent...

Adolescents' sun behaviour

A study of Scottish adolescents' sun behaviour found...

Melanoma guidelines

Melanoma guidelines

In a recent critical appraisal and review of melanoma...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases